Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter Completed Phase 2 Trials for Sorafenib (DB00398)

Also known as: Transitional cell cancer of the renal pelvis and ureter recurrent / Renal pelvis and ureter transitional cell cancer recurrent / Renal pelvis and ureteric cancer recurrent transitional cell / Renal pelvis and ureteral cancer transitional cell recurrent / Renal pelvis and ureteric cancer transitional cell recurrent

IndicationStatusPhase
DBCOND0028816 (Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00112671Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary TractTreatment